Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)	Application Number
1059.00051	09/914,277
Applicant	
Dexian Dou, et al.	
Filing Date	**Group Art Unit**
03/25/02	1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BL	3,791,932	02/12/74	Schuurs et al.			01/27/72
	3,839,153	10/01/74	Schuurs et al.			12/10/71
	3,850,752	11/26/74	Schuurs et al.			10/29/71
	3,850,578	11/26/74	McConnell			02/19/74
	3,853,987	12/10/74	Dreyer			09/01/71
	3,867,517	02/18/75	Ling			12/21/71
	3,879,262	04/22/75	Schuurs et al.			05/01/73
	3,901,654	08/26/75	Gross			06/21/71
	3,935,074	01/27/76	Rubenstein et al.			12/17/73
	3,984,533	10/05/76	Uzgiris			11/13/75
	3,996,345	12/07/76	Ullman et al.			03/30/75
	4,034,074	07/05/77	Miles			09/19/74
	4,098,876	07/04/78	Piasio et al.			10/26/76
	4,439,196	03/27/84	Higuchi			03/18/82
	4,447,224	05/08/84	DeCant, Jr. et al.			09/20/82
	4,447,233	05/08/84	Mayfield			07/30/82
	4,475,196	10/02/84	La Zor			03/06/81
	4,486,194	12/04/84	Ferrara			06/08/83
	4,487,603	12/11/84	Harris			11/26/82
	4,666,828	05/19/87	Gusella			08/15/84
	4,683,202	07/28/87	Mullis			10/25/85

BL	4,801,531	01/31/89	Frossard			09/30/85
	4,866,042	09/12/89	Neuwelt			11/18/87
	4,879,219	11/07/89	Wands et al.			09/19/80
	4,925,678	05/15/90	Ranney			04/01/87
	4,959,217	09/25/90	Sanders et al.			05/22/86
	5,011,771	04/30/91	Bellet et al.			09/24/87
	5,167,616	12/01/92	Haak et al.			12/14/89
	5,169,383	12/8/92	Gyory et al.			10/02/89
	5,192,659	03/09/93	Simons			07/11/90
	5,225,182	07/06/93	Sharma			10/31/91
	5,272,057	12/21/93	Smulson et al.			10/14/88
	5,281,521	01/25/94	Trojanowski et al.			07/20/92
	5,464,764	11/07/95	Capecchi et al.			02/04/93
	5,487,992	01/30/96	Capecchi et al.			06/28/93

FOREIGN PATENT DOCUMENTS

	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date Pertinent Pages, Etc.)*

BL		Ausubel et al. CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley and Sons, Baltimore, MD 1989.
		de Munk GA, Caspers MP, Chang GT, Pouwels PH, Enger-Valk BE, Verheijen JH. BINDING OF TISSUE-TYPE PLASMINOGEN ACTIVATOR TO LYSINE, LYSINE ANALOGUES, AND FIBRIN FRAGEMENTS, Biochemistry 1989, 28:7318-7325.
		Gilboa E, Eglitis, MA, Kantoff PW, Anderson WF. Transfer and Expression of Cloned Genes Using Retroviral Vectors, BioTechniques 1986, Vol. 4, No. 6, pages 504-512.
		Hanahan D, Folkman J. PATTERNS AND EMERGING MECHANISMS OF THE ANGIOGENIC SWITCH DURING TUMORIGENESIS, Cell 1996, 85:353-364.
		Harris AL. ARE ANGIOSTATIN AND ENDOSTATIN CURES FOR CANCER?, Lanet May 30, 1998, 351:1598-1599.
		Innis MA, Gelfand DH, Sninsky JJ, White, TJ. PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS, Academic Press, San Diego, CA 1990.
		Laemmli UK. CLEAVAGE OF STRUCTURAL PROTEINS DURING THE ASSEMBLY OF THE HEAD OF BACTERIOPHAGE T4, Nature 1970, 227(259):608-685.
		Marshak et al. STRATEGIES FOR PROTEIN PURIFICATION AND CHARACTERIZATION, CHSL Press 1996.
		Mishell and Shiligi (eds.) SELECTED METHODS IN CELLULAR IMMUNOLOGY, W.H. Freeman and Co., New York 1980.
		Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL, Cold Springs Harbor Laboratory, NY 1989 and 1992.
		Stites et al. (eds.) BASIC CLINICAL IMMUNOLOGY 8TH EDITION, Appleton & Lange, Norwalk, CT 1994.

BL		Testoni N, Marktel G, Farabegoli P, Zaccaria A, Amabile M, Raspadori D, Pelliconi, E, Carboni, Tura, S. A NEW METHOD OF "IN-CELL REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION" FOR THE DURATION OF BCR/ABL TRANSCRIPT IN CHRONIC MEYLOID LEUKEMIA PATIENTS, Blood May 1996, Vol 87, No. 9:3822-3827.
BL		Wu Z, O'Reilly MS, Folkman J, Shing Y. SUPPRESSION OF TUMOR GROWTH WITH RECOMBINANT MURINE ANGIOSTATIN, Biochemical and Biophysical Research Communications 1997, 236:651-654.

EXAMINER	DATE CONSIDERED
[signature]	7/15/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO/SB/ 08 (2-92)
DEPARTMENT OF COMMERCE

Patent and Trademark Office; U.S.

Form PTO-1449	Docket Number (Optional)	Application Number
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	1059.00051	09/914,277
	Applicant: Dexian Dou, et al.	
	Filing Date: 03/25/02	Group Art Unit: 1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date Pertinent Pages, Etc.)*

BL		Ault GS, Ryschkewitsch CF, Stoner GL. TYPE-SPECIFIC AMPLIFICATION OF VIRAL DNA USING TOUCHDOWN AND HOT START PCR, Journal of Virological Methods 1994, 46(2):145-156.
		Bicknell R, Harris AL. MECHANISMS AND THERAPEUTIC IMPLICATIONS OF ANGIOGENESIS, Current Opinion in Oncology 1996, 8:60-65.
		Browne ML et al. EXPRESSION OF RECOMBINANT HUMAN PLASMINOGEN AND AGLYCOPLASMINOGEN IN HeLa CELLS, Fibrinolysis 1991, Vol 5(4), 257-260.
		Dameron KM, Volpert OV, Tainsky MA, Bouck N. CONTROL OF ANGIOGENESIS OM FIBROBLASTS BY p53 REGULATION OF THROMBOSPONDIN-1, Science 1994; 265:1582-1584.
		Fisher B, Gunduz N, Coyle J, Rudock C, Saffer EA. PRESENCE OF A GROWTH-STIMULATING FACTOR IN SERUM FOLLOWING PRIMARY TUMOR REMOVAL IN MICE, Cancer Research 1989, 49:1996-2001.
		Folkman I, Sing Y. ANGIOGENESIS, Biol Chem 1992, 267:10931.
		Folkman J, Haudenschild CC, Zetter BR. LONG-TERM CULTURE OF CAPILLARY ENDOTHELIAL CELLS, Proc Natl Acad Sci USA 1979, 76:5217-5221.
		Folkman J. ANGIOGENISIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE, Nature Medicine 1995, 1(1):27-31.
		Folkman J. TUMOR ANGIOGENESIS: THERAPEUTIC IMPLICATIONS, N. Eng J Med 285:1182, 1971.
		Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. THE MECHANISM OF CANCER-MEDIATED CONVERSION OF PLASMINOGEN TO THE ANGIOGENESIS INHIBITOR ANGIOSTATIN, Proceedings of the National Academy of Sciences of the United States of America, 1997, 94(20):10868-10872.
		Kohn EC, Liotta La. MOLECULAR INSIGHTS INTO CANCER INVASION: STRATEGIES FOR PREVENTION AND INTERVENTION, Cancer Res 1995, 55:1856-1860.
		Liotta LA, Kleinerman J, Saidel G. QUANTITATIVE RELATIONSHIPS OF INTRAVASCULAR TUMOR CELLS: TUMOR VESSELS AND PULMONARY METASTASES FOLLOWING TUMOR IMPLANTATION, Cancer Res 1974, 34:997-1003.
		Lokker NA, Presta LG, Godowski PJ. MUTATIONAL ANALYSIS AND MOLECULAR MODELING OF THE N-t~ KRINGLE-CONTAINING DOMAIN OF HEPATOCYTE GROWTH FACTOR IDENTIFIES AMINO ACID SIDE CHAINS IMPORTANT FOR INTERACTION WITH THE c-Met RECEPTOR, Protein Engineering 1994, 7(7):895-903.
		Maione T, Gray GS, Petro AJ, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ. INHIBITION OF ANGIOGENESIS BY RECOMBINANT HUMAN PLATELET FACTOR-4 AND RELATED PEPTIDES, Science 1990, 247:77-79.
		Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF, Rosenblum ML. IMMUNOLOCALIZATION OF CATHEPSIN B IN HUMAN GLIOMA: IMPLICATIONS FOR TUMOR INVASION AND ANGIOGENESIS, Neurosurg. 1995, 83:285-290.

		Mulder M, Kohnert U, Fischer S, van Hinsbergh VW, Verheijen JH. THE INTERACTION OF RECOMBINANT TISSUE TYPE PLASMINOGEN ACTIVATOR AND RECOMBINANT PLASMINOGEN ACTIVATOR (r-PA/BM 06.022) WITH HUMAN ENDOTHELIAL CELLS, Blood Coagulation and Fibrinolysis 1997, 8:124-133.
		Nelson J, Allen W, Scott W, Bailie J, Walker B, McFerran N., Wilson, D. MURINE EPIDERMAL GROWTH FACTOR (EGF) FRAGMENT (33-42) INHIBITS BOTH EGF- AND LAMININ-DEPENDENT ENDOTHELIAL CELL MOTILITY AND ANGIOGENESIS, Cancer Research 1995, 55:3772-3776.
		Nilsen SL, DeFord ME, Prorok M, Chibber BAK, Bretthauer RK, Castellino FJ. HIGH-LEVEL SECRETION IN PICHIA PASTORIS AND BIOCHEMICAL CHARACTERIZATION OF THE RECOMBINANT KRINGLE 2 DOMAIN OF TISSUE-TYPE PLASMINOGEN ACTIVATOR, Biotechnol Appl Biochem 1997, 25:63-74.
		Pennica D, Holmes, WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Colleen D. CLONING AND EXPRESSION OF HUMAN TISSUE-TYPE PLASMINOGEN ACTIVATOR cDNA IN *E. coli*, Nature 1983, 301214-221.
		Perbal. A PRACTICAL GUIDE TO MOLECULAR CLONING, John Wiley & Sons, New York 1988.
		Polverini PJ, Bouck NP, Rastinejad F. ASSAY AND PURIFICATION OF NATURALLY OCCURRING INHIBITOR OF ANGIOGENESIS. Methods Enzymol 1991, 198:440-450.
		Rodriguez,RL and Denhardt DT, eds. VECTORS: A SURVEY OF MOLECULAR CLONING VECTORS AND THEIR USES, Butterworths, Boston, MA 1988.
		Sanger F, Air GM, Barrell BG, Brown NL, Coulson AR, Fiddes CA, Hutchison CA, Clocombe PM, Smith M. NUCLIOTIDE SEQUENCE OF BACTERIOPHAGE PHI X174 DNA, Nature 1977, 265(5596):687-695.
		Simpson-Herren L, Sanford AH, Holmquist JP. EFFECTS OF SURGERY ON THE CELL KINETICS ON RESIDUAL TUMOR, Cancer Treat. Rep. 1976, 60:1749-1760.
		Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. PEPTIDES DERIVED FROM TWO SEPARATE DOMAINS OF THE MATRIX PROTEIN THROMBOSPONDIN-1 HAVE ANTI-ANGIOGENIC ACTIVITY, Journal of Cell Biology 1993, Vol. 122, No. 2, pgs 497-511.
		Topol EJ, Califf RM, George BS, Caracas DJ, Lee KL. INSIGHTS DERIVED FROM THE THROMBOLYSIS AND ANGIOPLASTY IN MYOCARDIAL INFARCTION (TAMI) Trials, Journal of the American College of Cardiology 1988, 12(6 Suppl. A),24A-31A.
		Urano T, Takada Y, Takada A. STIMULATION OF THE AMIDOLYTIC ACTIVITY OF SINGLE CHAIN TISSUE-TYPE PLASMINOGEN ACTIVATOR BY FIBRINOGEN DEGRADATION PRODUCT: POSSIBLE FIBRIN BINDING SITES ON SINGLE CHAIN TISSUE-TYPE PLASMINOGEN ACTIVATOR MOLECULE, Biochimica et Biosphysica Acta 1991, 1077:245-252.
		Vega et al. GENE TARGETING, CRC Press, Ann Arbor, MI 1995.
		Watson et al. RECOMBINANT DNA, Scientific American Books, New York, 1992.
		Wilson C, Goberdhan DC, Steller H, Dror. A POTENTIAL NEUTOTROPHIC RECEPTOR GENE, ENCODES A DROSOPHILA HOMOLOG OF THE VERTEBRATE Ror FAMILY OF Trk-RELATED RECEPTOR TYROSINE KINASES, Proceedings of the National Academy of Sciences of the United States of America 1993, 90(15):7109-7113.

EXAMINER	DATE CONSIDERED
	7/15/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO/SB/ 08 (2-92)
DEPARTMENT OF COMMERCE

Patent and Trademark Office; U.S.

MANUAL OF PATENT EXAMINING PROCEDURE

Form PTO-1449

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)	Application Number
1059.00051	09/914,277
Applicant: Dexian Dou, et al.	
Filing Date: 03/25/02	Group Art Unit: 1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHER DOCUMENTS *(Including Author, Title, Date Pertinent Pages, Etc.)*

BL		Bennett WF, Paoni NF, Keyt BA, Botstein D, Jones AJ, Presta L, Wurm FM, Zoller MJ. HIGH RESOLUTION ANALYSIS OF FUNCTIONAL DETERMINANTS ON HUMAN TISSUE-TYPE PLASMINOGEN ACTIVATOR, Journal of Biological Chemistry 1991, 266(8):5191-5201.
		Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O'Reilly MS, Llinas M, Folkman J. KRINGLE DOMAINS OF HUMAN ANGIOSTATIN. CHARACTERIZATION OF THE ANTI-PROLIFERATION ACTIVITY ON ENDOTHELIAL CELLS, Journal of Biological Chemistry 1996; 271:297431-29467.
		Cao Y., Chen A, An SSA, Ji RW, Davidson D, Llinas M. KRINGLE 5 OF PLASMINOGEN IS A NOVEL INHIBITOR OF ENDOTHELIAL CELL GROWTH, Journal of Biological Chemistry 1997, 272:22924-22928.
		Chang et al. SOMATIC GENE THERAPY, CRC Press, Ann Arbor, MI 1995.
		Cheng XF, Brohlin M, Pohl G, Back O, Wallen P. BINDING OF TISSUE PLASMINOGEN ACTIVATOR TO ENDOTHELIAL CELLS, Thrombosis Research 1955, 77(2)149-164.
		Dong Z, Kumar R, Yang X, Fidler IJ. MACROPHAGE-DERIVED METALLOELASTASE IS RESPONSIBLE FOR THE GENERATION OF ANGIOSTATIN IN LEWIS LUNG CARCINOMA, C II 1997, 88:801-810.
		Dunn T. OXYGEN AND CANCER, NorthCarolina Medical Journal 1997,58:140-143.
		Fisher B, Gunduz N, Saffer EA. INFLUENCE OF THE INTERVAL BETWEEN PRIMARY TUMOR REMOVAL AND CHEMOTHERAPY ON KINETICS AND GROWTH OF METASTASES, Cancer Research, 43:1488-1492, 1983.
		Folkman J, D'Amore PA, BLOOD VESSEL FORMATION: WHAT IS ITS MOLECULAR BASIS?, Cell 1996, 87(7):1153-1155.
		Forsgren M, Råden B, Israelsson M, Larsson K, HedÉn LO. MOLECULAR CLONING AND CHARACTERIZATION OF A FULL-LENGTH cDNA CLONE FOR HUMAN PLASMINOGEN. FEBS Letters 1987, 213(2):254-260.
		Garcia G, Mar P, Mullin D, Walker J, Prather N. THE *E coli* dna Y GENE ENDOCES AN ARGININE TRANSFER RNA, Cell 1986, 45:453-459.
		Goldhaber SI, Kessler CM, Heit J, Markis J, Sharma GV, Dawley D, Nagel JS, Meyerovitz M, Kim D, Vaughn DE. RANDOMIZED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM, Lancet 1988, 2(8606):293-298.
		Horrevoets A, Smilde A, de Vries C, Pannekoek H. THE SPECIFIC ROLES OF FINGER AND KRINGLE 2 DOMAINS OF TISSUE-TYPE PLASMINOGEN ACTIVATOR DURING IN VITRO FIBRINOLYSIS, Journal of Biological Chemistry 1994, 269(17):12639-12644.

		Hruska KA, Rolnick F, Huskey M, Alvarez U, Cheresh D. ENGAGEMENT OF THE OSTEOCLAST INTEGRIN ALPHA V BETA 3 BY OSTEOPONTIN STIMULATES PHOSPHATIDYLINOSITOL 3-HYDROXYL KINASE ACTIVITY, Endocrinology 1995, 136(7):2984-2992.
		Hu GF. LIMITED PROTEOLYSIS OF ANGIOSTATIN BY ELASTASE IS REGULATED BY PLASMINOGEN, J Protein Chem 1997, 16:669-679.
		Jendrasschak E., Sage EH. REGULATION OF ANGIOGENESIS BY SPARC AND ANGIOSTATIN: IMPLICATIONS FOR TUMOR CELL BIOLOGY, Seminars in Cancer Biology 1996, 7:139-146.
		Ji WR, Barrientos LG, Llinas M, Gray H, Villarreal X, DeFord ME, Castellino FJ, Kramer RA, Trail PA. SELECTIVE INHIBITION BY KRINGLE 5 OF HUMAN PLASMINOGEN ON ENDOTHELUAL CELL MIGRATION, AN IMPORTANT PROCESS IN ANGIOGENESIS, Biochemical and Biophysical Research Communications 1998, 247:414-419.
		Liotta LA, Steeg PS, Stetler-Stevenson WG. CANCER METASTASIS AND ANGIOGENESIS; AN IMBALANCE OF POSITIVE AND NEGATIVE REGULATION, Cell 1991, 64:327-336.
		The National Institute of Neurological Disorders and Stoke (NINDS) rt-PA Stroke Study Group, A SYSTEM APPROACH TO IMMEDIATE EVALUATION AND MANAGEMENT OF HYPERACUTE STROKE. EXPERIENCE AT EIGHT CENTERS AND IMPLICATIONS FOR COMMUNITY PRACTICE AND PATIENT CARE, Stroke 1997, 28(8):1530-1540.
		Nesheim M, Fredenburgh JC, Larsen GR. THE DISSOCIATION CONSTANTS AND STOICHIOMETRIES OF THE INTERACTIONS OF LYS-PLASMINOGEN AND CHLOROMETHYL KETONE DERIVATIVES OF TISSUE PLASMINOGEN ACTIVATOR AND THE VARIANT DELTA FE IX WITH INTACT FIBRIN, Journal of Biological Chemistry 1990, 265(35) 21541-21548.
		O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, Flynn E, Birkhead J, Olsen B, Folkman J. ENDOSTATIN: AN ENDOGENOUS INHIBITOR OF ANGIOGENSIS AND TUMOR GROWTH, Cell 1997, 88:277-285.
		O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M, Lane W, Cao Y, Sage EH, Folkman J. ANGIOSTATIN: A NOVEL ANGIOGENESIS INHIBITOR THAT MEDIATES THE SUPPRESSION OF METASTASES BY A LEWIS LUNG CARCINOMA, Cell 1994, 79:315-328.
		O'Reilly M, Rosenthal R, Sage EH, Smith S, Holmgren L, Moses M, Shing Y, Folkman J. THE SUPPRESSION OF TUMOR METASTASES BY A PRIMARY TUMOR, Surg Forum 1993, 44:474-476.
		O'Reilly MS, Holmgren L, Chen C, Folkman J. ANGIOSTATIN INDUCES AND SUSTAINS DORMANCY OF HUMAN PRIMARY TUMORS IN MICE, Nature Med 1996, 2:689-692.
		Parker JA, Markis JE, Palla A, Goldhaber SZ, Royal HD, Tumeh S, Kim D, Rustgi AK, Holman BL, Kolodny GM. PULMONARY PERFUSION AFTER rt-PA THERAPY FOR ACUTE EMBOLISM: EARLY IMPROVEMENT ASSESSED WITH SEGMENTAL PERFUSION SCANNING, Radiology 1988, 166(2):441-445.
		Patterson BC, Sang QA. ANGIOSTATIN-CONVERTING ENZYME ACTIVITIES OF HUMAN MATRILYSIN (MMP-7) AND GELATINASE B/TYPE IV COLLAGENASE (MMP-9), J Biol Chem 1997, 272:28823-28825.
		Patthy L. EVOLUTION OF THE PROTEASES OF BLOOD COAGULATION AND FIBRINOLYSIS BY ASSEMBLY FROM MODULES, Cell 1985, 41(3):657-663.
		Saarela J, Ylikarppa R, Rehn M, Purmonen S, Pihlajaniemi T. COMPLETE PRIMARY STRUCTURE OF TWO VARIANT FORMS OF HUMAN TYPE XVIII COLLAGEN AND TISSUE-SPECIFIC DIFFERENCES IN THE EXPRESSION OF THE CORRESPONDING TRANSCRIPTS, Matrix Biology 1997, 16:319-328.
		Standker L, Schrader M, Kanse SM, Jurgens M, Forssmann WG, Preissner KT. ISOLATION AND CHARACTERIZATION OF THE CIRCULATING FORM OF HUMAN ENDOSTATIN. FEBS Letters 1997, 420(2-3):129-133.
		Stathakis P, Fitsgerald M, Mathrhais LJ, Chesterman CN, Hogg PJ. GENERATION OF ANGIOSTATIN BY REDUCTION AND PROTEOLYSIS PF PLASMIN. CATALYSIS BY A PLASMIN REDUCTASE SECRETED BY CULTURED CELLS, J. Biol Chem 1997, 272:20647-20645.
		Stump DC, Califf RM, Topol EJ, Sigmon K, Thorton D, Masek R, Anderson L, Collen D. PHARMACODYNAMICS OF THROMBOLYSIS WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR. CORRELATIONS WITH CHARACTERISTICS OF AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, The TAMI Study Group, Circulation 1989, 80(5)1222-1230.
		Thimmer R, Spangenberg HC, Blum HE. ANGIOSTATIN. A BIOLOGICAL INHIBITOR OF TUMOR ANGIOGENESIS, Deutsche Medizinische Wochenschrift 1997, 122:413-414.
		Wardlaw JM, Warlow CP, Consell C. SYSTEMATIC REVIEW OF EVIDENCE ON THROMBOLYTIC THERAPY FOR ACUTE ISCHAEMIC STOKE, Lancet 1997, 350(9078):607-614.

BL		White FC, Carroll SM, Kamps MP. VEGF mRNA IS REVERSIBLY STABILIZED BY HYPOXIA AND PERSISTENTLY STABILIZED IN VEGF-OVEREXPRESSING HUMAN TUMOR CELL LINE, Growth Factors 1995, 12(4):289-301.
EXAMINER		DATE CONSIDERED
		2/15/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO/SB/ 08 (2-92)
DEPARTMENT OF COMMERCE
Patent and Trademark Office; U.S.